论文部分内容阅读
我国是乙肝高发区,据文献报导,群体乙肝病毒(HBV)总感染率为57.6％,HBV表面抗原(HBsAg)携带率9.75％,HBV影响面广,对人类健康危害较大,目前无彻底清除HBV的药物。我们用乙肝宁与盐酸左旋咪唑(Levamisole HCI)治疗乙型肝炎,收到满意效果,现报告如下。1 对象 1995年10月～1997年12月在我院检出260例HBsAg携带者,做丙氨酸精氨酶(ALT),乙肝五项指标检验,从中筛选携带者HBsAg,HBeAg至少两项阳性的病例120例,且包括8例ALT增高的患者。随机分成两组,治疗组59例,男31例,女28例,年龄15～52岁(39.5岁);对照组51例,男28例,女23例,年龄16～50岁(41.5岁)。
China is a high-incidence area of hepatitis B. According to the literature, the total infection rate of population is 57.6%. The carrier rate of HBV surface antigen (HBsAg) is 9.75%. HBV has a wide impact on human health and is not completely eliminated at present HBV drug. We use hepatitis B and levamisole hydrochloride (Levamisole HCI) treatment of hepatitis B, received satisfactory results, are as follows. 1 object From October 1995 to December 1997 in our hospital detected 260 cases of HBsAg carriers, alanine aminotransferase (ALT), hepatitis B five indicators test, screening carriers HBsAg, HBeAg at least two positive Of the 120 cases, and including 8 patients with elevated ALT. There were 59 cases in the treatment group, including 31 males and 28 females, ranging in age from 15 to 52 years (39.5 years). The control group consisted of 51 males and 28 females, 23 females, aged from 16 to 50 years (41.5 years) .